國家衛生研究院 NHRI:Item 3990099045/9351
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 913357      在线人数 : 1147
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/9351


    题名: The safety and efficacy of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan
    作者: Chou, WC;Liu, CT;Chen, MH;Lu, CH;Ku, FC;Su, YL;Shan, YS;Chen, LT;Chen, YY;Chen, JS
    贡献者: National Institute of Cancer Research
    摘要: Renoprotective effect of combining pentoxifylline with renin-angiotensin-aldosterone system blockade in pre-dialyzed advanced chronic kidney disease patients - a ntionwide database analysis. Objective: Everolimus is an inhibitor of the mammalian target of rapamycin. It has been approved for patients with advanced pancreatic neuroendocrine tumors (NETs) since 2011. This study aimed to evaluate the safety and efficacy of everolimus in Taiwanese patients with progressive, advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Methods: Forty-six patients with progressive, advanced GEP-NETs who received everolimus treatment between January 2008 and August 2014 at six medical centers across Taiwan were selected. Patient’s characteristics, tumor features, safety profiles and treatment efficacy with everolimus were retrospectively analyzed from medical charts. Results: The median follow up duration was 20.1 (range 1.2–67.6) months and 35 of 46 patients (76.1%) remained alive at the end of study. The 1- and 2-year overall survival rates were 91.3% and 71.7%, respectively. The median progression free survival (PFS) was 17.0 (range 6.8–27.1) months. Regarding the best response of everolimus treatment, 11 (19.0%) patients had partial response, 27 (46.6%) patients had stable disease and 8 (13.8%) patients had progressive disease. Patients with World Health Organization (WHO) grade 1 NETs, nonfunctional tumor, not use of somatostatin analogue and use only one targeting agent everolimus rather than two lines of targeting agent or more had significant better PFS under everolimus treatment. The most common adverse events associated with everolimus were stomatitis (31.1%), rash (22.2%), and hyperglycemia (17.1%). Seven (15.4%) patients experienced severe adverse events (grade III or more). Grade III adverse events included hyperglycemia (4.4%), anemia (4.4%), fatigue (2.2%), and elevated liver function test (2.2%).One (2.2%) patient death due to grade V interstitial pneumonitis. Conclusions: Everolimus was an effective treatment option for Taiwanese patients with progressive, advanced GEP NETs. Clinicians must be aware of and able to manage common adverse events to maximize patient compliance with everolimus.
    日期: 2015-09
    關聯: European Journal of Cancer. 2015 Sep;51(Suppl. 3):S459.
    Link to: http://dx.doi.org/10.1016/S0959-8049(15)30047-2
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0959-8049&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000361887402165
    显示于类别:[陳立宗] 會議論文/會議摘要

    文件中的档案:

    档案 描述 大小格式浏览次数
    ISI000361887402165.pdf41KbAdobe PDF357检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈